Marble Harbor Investment Counsel LLC Raises Stock Holdings in Stryker Corporation $SYK

Marble Harbor Investment Counsel LLC boosted its position in shares of Stryker Corporation (NYSE:SYK) by 1.2% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,136 shares of the medical technology company’s stock after buying an additional 336 shares during the quarter. Stryker accounts for approximately 1.2% of Marble Harbor Investment Counsel LLC’s investment portfolio, making the stock its 28th largest position. Marble Harbor Investment Counsel LLC’s holdings in Stryker were worth $11,131,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. lifted its position in shares of Stryker by 1.7% in the 2nd quarter. PNC Financial Services Group Inc. now owns 1,050,602 shares of the medical technology company’s stock worth $415,650,000 after purchasing an additional 17,278 shares during the period. Wealth Alliance LLC grew its position in shares of Stryker by 2.1% in the 2nd quarter. Wealth Alliance LLC now owns 1,900 shares of the medical technology company’s stock worth $752,000 after buying an additional 39 shares during the last quarter. Forsta AP Fonden grew its position in shares of Stryker by 1.1% in the 2nd quarter. Forsta AP Fonden now owns 91,153 shares of the medical technology company’s stock worth $36,063,000 after buying an additional 1,000 shares during the last quarter. Davidson Capital Management Inc. lifted its position in Stryker by 2.0% during the second quarter. Davidson Capital Management Inc. now owns 8,731 shares of the medical technology company’s stock valued at $3,454,000 after acquiring an additional 168 shares during the last quarter. Finally, CENTRAL TRUST Co boosted its stake in Stryker by 5.2% in the second quarter. CENTRAL TRUST Co now owns 17,306 shares of the medical technology company’s stock valued at $6,847,000 after acquiring an additional 854 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In related news, insider Viju Menon sold 500 shares of the stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 276,173 shares of the business’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the transaction, the director owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 520,500 shares of company stock worth $184,803,065. Company insiders own 5.20% of the company’s stock.

Stryker Stock Performance

SYK opened at $363.68 on Wednesday. The firm’s fifty day simple moving average is $373.39 and its two-hundred day simple moving average is $381.33. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19. The company has a market cap of $139.08 billion, a price-to-earnings ratio of 48.17, a PEG ratio of 2.66 and a beta of 0.94. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. The business had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the business earned $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Rothschild & Co Redburn initiated coverage on shares of Stryker in a report on Thursday, September 18th. They set a “neutral” rating and a $420.00 price objective on the stock. Evercore ISI decreased their price target on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a report on Friday, October 31st. BTIG Research boosted their price objective on shares of Stryker from $408.00 to $410.00 and gave the company a “buy” rating in a report on Friday, October 31st. Truist Financial reissued a “hold” rating and issued a $392.00 target price (down from $407.00) on shares of Stryker in a research report on Monday, November 3rd. Finally, Barclays boosted their price target on Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Thirteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $433.37.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.